Your browser doesn't support javascript.
loading
Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
Sousa, Nadia; Geiß, Carsten; Bindila, Laura; Lieberwirth, Ingo; Kim, Ella; Régnier-Vigouroux, Anne.
Affiliation
  • Sousa N; Institute of Developmental Biology & Neurobiology, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Geiß C; Institute of Developmental Biology & Neurobiology, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Bindila L; Clinical Lipidomics Unit, Institute of Physiological Chemistry, Medical University Mainz, Mainz, Germany.
  • Lieberwirth I; Max Planck Institute for Polymer Research, Mainz, Germany.
  • Kim E; Department of Neurosurgery, Medical University of Mainz, Mainz, Germany.
  • Régnier-Vigouroux A; Institute of Developmental Biology & Neurobiology, Johannes Gutenberg University Mainz, Mainz, Germany. vigouroux@uni-mainz.de.
BMC Cancer ; 23(1): 762, 2023 Aug 16.
Article in En | MEDLINE | ID: mdl-37587449
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Glioblastoma / Antineoplastic Agents Limits: Humans Language: En Journal: BMC Cancer Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Glioblastoma / Antineoplastic Agents Limits: Humans Language: En Journal: BMC Cancer Year: 2023 Document type: Article